Pfizer CEO Contracts COVID-19 Infection For Second Time
Pfizer Inc's (NYSE: PFE) CEO Albert Bourla said he had tested positive for COVID-19.
"I'm feeling well and symptom-free," 60-year-old Bourla said in a statement. In August, he contacted COVID and received one course of paxlovid, Pfizer's oral COVID-19 antiviral treatment.
Bourla has received four doses of the COVID vaccine developed by Pfizer and BioNTech SE (NASDAQ: BNTX).
Bourla said he has not yet taken the new bivalent booster.
Developed by Moderna Inc (NASDAQ: MRNA) and Pfizer/BioNTech, the updated bivalent shots aim to tackle the BA.5 and BA.4 Omicron subvariants, which make up 84.8% and 1.8%, respectively, of all circulating variants in the U.S., based on latest data, Reuters reported.
"I've not had the new bivalent booster yet, as I was following CDC guidelines to wait three months since my previous COVID case, which was back in mid-August," Bourla added.
A federal health agency said that over 25 million doses of the so-called bivalent shots had been sent out this week, mainly from Pfizer/BioNTech vaccine, as production of the Moderna vaccine ramps up.
Price Action: PFE shares are down 0.66% at $43.79 during the premarket session on the last check Monday.
See more from Benzinga
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Kids, But Scrambles Supply Challenges
Switzerland To Dispose 10M Expired COVID-19 Vaccine Doses From Moderna
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.